{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:43:30Z","timestamp":1792755810449,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40122-022-00452-3","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T04:12:59Z","timestamp":1669176779000},"page":"251-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effectiveness and Safety of Chronic Migraine Preventive Treatments: A Systematic Literature Review"],"prefix":"10.1007","volume":"12","author":[{"given":"Andrew M.","family":"Blumenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anadi","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemlata","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-5872","authenticated-orcid":false,"given":"Katherine","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Knievel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"452_CR1","unstructured":"International Headache Society. 2019 [cited 2020 12 September]. https:\/\/ichd-3.org\/1-migraine\/1-3-chronic-migraine\/. Accessed 12 Sep 2022."},{"key":"452_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P, et\u00a0al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20:92.","journal-title":"J Headache Pain"},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM, Serrano D, Buse DC, et\u00a0al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35:563\u201378.","journal-title":"Cephalalgia"},{"key":"452_CR4","first-page":"41","volume":"59","author":"R Burch","year":"2019","unstructured":"Burch R, Hettie B. Longitudinal preventive medication use patterns in patients receiving onabotulinumtoxina treatment: a chart review study. Headache. 2019;59:41\u20132.","journal-title":"Headache"},{"key":"452_CR5","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/head.13202","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57:1532\u201344.","journal-title":"Headache"},{"key":"452_CR6","first-page":"22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20:22\u201333.","journal-title":"J Manag Care Pharm"},{"key":"452_CR7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478\u201388.","journal-title":"Cephalalgia"},{"key":"452_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40265-018-0894-6","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018;78:589\u2013600.","journal-title":"Drugs"},{"key":"452_CR9","first-page":"1003","volume":"11","author":"R Gooriah","year":"2015","unstructured":"Gooriah R, Ahmed F. OnabotulinumtoxinA for chronic migraine: a critical appraisal. Ther Clin Risk Manag. 2015;11:1003\u201313.","journal-title":"Ther Clin Risk Manag"},{"key":"452_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-017-0776-4","volume":"18","author":"K Le","year":"2017","unstructured":"Le K, Yu D, Wang J, Ali AI, Guo Y. Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials. J Headache Pain. 2017;18:69.","journal-title":"J Headache Pain"},{"key":"452_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, et\u00a0al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6.","journal-title":"J Headache Pain"},{"key":"452_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.amjmed.2020.01.031","volume":"133","author":"BL Spindler","year":"2020","unstructured":"Spindler BL, Ryan M. Medications approved for preventing migraine headaches. Am J Med. 2020;133:664\u20137.","journal-title":"Am J Med"},{"key":"452_CR13","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/head.13653","volume":"59","author":"JF Rothrock","year":"2019","unstructured":"Rothrock JF, Adams AM, Lipton RB, et\u00a0al. FORWARD Study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache. 2019;59:1700\u201313.","journal-title":"Headache"},{"key":"452_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"452_CR15","unstructured":"Wells G SB, O\u2019Connell D, Peterson J, Welch V, Losos M, et\u00a0al,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013 [cited 2020 11 September ]. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 11 Sep 2022."},{"key":"452_CR16","first-page":"S60","volume":"25","author":"P Taddei-Allen","year":"2019","unstructured":"Taddei-Allen P, Deleon L, Oelofsen M, Page N. Comparing patient-reported outcomes in patients using CGRP antagonists or onabotulinumtoxinA for chronic migraine. J Manag Care Spec Pharm. 2019;25:S60.","journal-title":"J Manag Care Spec Pharm"},{"key":"452_CR17","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1177\/0333102417724150","volume":"37","author":"M Matharu","year":"2017","unstructured":"Matharu M, Pascual J, Nilsson R, et\u00a0al. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017;37:1384\u201397.","journal-title":"Cephalalgia"},{"key":"452_CR18","unstructured":"Garcia-Azorin D, Ruiz-Pinero M, Sierra A, Martinez B, Guerrero Peral AL. Habituation determined by algometry as a marker of response in chronic migraine. J Headache Pain. 2018;19(Suppl 1):80. Abstract P154."},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jns.2016.01.054","volume":"363","author":"MJ Lee","year":"2016","unstructured":"Lee MJ, Lee C, Choi H, Chung C. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: a clinic-based prospective study. J Neurol Sci. 2016;363:51\u20134.","journal-title":"J Neurol Sci"},{"key":"452_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s40064-015-1386-8","volume":"4","author":"F Ahmed","year":"2015","unstructured":"Ahmed F, Zafar HW, Buture A, Khalil M. Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. Springerplus. 2015;4:589.","journal-title":"Springerplus"},{"key":"452_CR21","doi-asserted-by":"crossref","unstructured":"Aydinlar EI, Dikmen PY, Kosak S, Kocaman AS. OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study. J Headache Pain. 2017;18:23.","DOI":"10.1186\/s10194-017-0723-4"},{"key":"452_CR22","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jpain.2017.02.345","volume":"18","author":"P Flood","year":"2017","unstructured":"Flood P, Barad M, Sturgeon J, Kao M, Fish S, Mackey S. PREEMPT: Prospective from complex patients in practice. J Pain. 2017;18:S67.","journal-title":"J Pain"},{"key":"452_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/head.13211","volume":"58","author":"C Dom\u00ednguez","year":"2018","unstructured":"Dom\u00ednguez C, Vieites-Prado A, P\u00e9rez-Mato M, et\u00a0al. CGRP and PTX3 as predictors of efficacy of Onabotulinumtoxin type a in chronic migraine: an observational study. Headache. 2018;58:78\u201387.","journal-title":"Headache"},{"key":"452_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s10072-016-2568-z","volume":"37","author":"M Russo","year":"2016","unstructured":"Russo M, Manzoni GC, Taga A, et\u00a0al. The use of onabotulinum toxin A (Botox\u00ae) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. Neurol Sci. 2016;37:1127\u201331.","journal-title":"Neurol Sci"},{"key":"452_CR25","doi-asserted-by":"crossref","unstructured":"Schiano di Cola F, Caratozzolo S, Liberini P, Rao R, Padovani A. Response predictors in chronic migraine: Medication overuse and depressive symptoms negatively impact onabotulinumtoxin-A treatment. Front Neurol. 2019;10:678.","DOI":"10.3389\/fneur.2019.00678"},{"key":"452_CR26","doi-asserted-by":"crossref","unstructured":"Aicua-Rapun I, Mart\u00ednez-Velasco E, Rojo A, et\u00a0al. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year. J Headache Pain. 2016;17:112.","DOI":"10.1186\/s10194-016-0702-1"},{"key":"452_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11055-019-00862-5","volume":"50","author":"MV Naprienko","year":"2020","unstructured":"Naprienko MV, Smekalkina LV, Safonov MI, et\u00a0al. The burden of migraine in real clinical practice: clinical and economic aspects. Neurosci Behav Physiol. 2020;50:20\u20136.","journal-title":"Neurosci Behav Physiol"},{"key":"452_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-016-0591-3","volume":"17","author":"A Negro","year":"2016","unstructured":"Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2016;17:1\u20139.","journal-title":"J Headache Pain"},{"key":"452_CR29","doi-asserted-by":"crossref","unstructured":"Guerzoni S PL, Baraldi C, Cainazzo MM, Negro A, Martelletti P, Pini LA. Long-term treatment benefits and prolonged efficacy of OnabotulinumtoxinA in patients affected by chronic migraine and medication overuse headache over 3 years of therapy. Front Neurol. 2017;8:586.","DOI":"10.3389\/fneur.2017.00586"},{"key":"452_CR30","doi-asserted-by":"publisher","unstructured":"Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont-Benjamin L. Effectiveness of onabotulinumtoxinA (BOTOX\u00ae) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data. Cephalalgia. 2022. https:\/\/doi.org\/10.1177\/03331024221123058.","DOI":"10.1177\/03331024221123058"},{"key":"452_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","volume":"20","author":"F Ahmed","year":"2019","unstructured":"Ahmed F, Gaul C, Garc\u00eda-Monc\u00f3 JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20:26.","journal-title":"J Headache Pain"},{"key":"452_CR32","unstructured":"Alessiani M, Petolicchio B, Vigano A, et\u00a0al. Short-term psychodynamic psychotherapy versus onabotulinumtoxinA as preventive therapy in chronic migraine: a real world study. J Headache Pain. 2018;19(Suppl 1):80. Abstract O50."},{"key":"452_CR33","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/ene.14028","volume":"26","author":"A Alpuente","year":"2019","unstructured":"Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P. Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA. Eur J Neurol. 2019;26:1464\u201370.","journal-title":"Eur J Neurol"},{"key":"452_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ene.13657","volume":"25","author":"AP Andreou","year":"2018","unstructured":"Andreou AP, Trimboli M, Al-Kaisy A, et\u00a0al. Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. Eur J Neurol. 2018;25:1069\u201375.","journal-title":"Eur J Neurol"},{"key":"452_CR35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/rapm-2018-100196","volume":"44","author":"M Barad","year":"2019","unstructured":"Barad M, Sturgeon JA, Fish S, Dexter F, Mackey S, Flood PD. Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain. Reg Anesth Pain Med. 2019;44:660\u20138.","journal-title":"Reg Anesth Pain Med"},{"key":"452_CR36","first-page":"262","volume":"39","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Vernieri F. Erenumab in migraine: the first Italian real-life data. Cephalalgia. 2019;39:262\u20133.","journal-title":"Cephalalgia"},{"key":"452_CR37","first-page":"P98-P","volume":"18","author":"R Belv\u00eds","year":"2018","unstructured":"Belv\u00eds R, Moroll\u00f3n N, Guasch M, Marrero P, Azahara A, Roig C. Effectiveness of OnabotulinumtoxinA in chronic migraine. If early introduction: faster, cheaper and more satisfactory. J Headache Pain. 2018;18:P98-P.","journal-title":"J Headache Pain"},{"key":"452_CR38","first-page":"94","volume":"58","author":"G Boudreau","year":"2018","unstructured":"Boudreau G, Becker WJ, Graboski C, et\u00a0al. Impact of onabotulinumtoxina on quality of life, health resource utilization, and work productivity in people with chronic migraine: interim results from a prospective, observational study (PREDICT). Headache. 2018;58:94.","journal-title":"Headache"},{"key":"452_CR39","first-page":"367","volume":"39","author":"GP Boudreau","year":"2019","unstructured":"Boudreau GP, Demers C. Treatment of chronic migraine with Erenumab alone or as an add on therapy; a real world prospective observational study. Cephalalgia. 2019;39:367.","journal-title":"Cephalalgia"},{"key":"452_CR40","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s10072-016-2662-2","volume":"37","author":"C Butera","year":"2016","unstructured":"Butera C, Colombo B, Bianchi F, et\u00a0al. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A? Neurol Sci. 2016;37:1701\u20136.","journal-title":"Neurol Sci"},{"key":"452_CR41","doi-asserted-by":"crossref","unstructured":"Caronna E, Gallardo VJ, Hern\u00e1ndez-Beltr\u00e1n N, Torres-Ferrus M, Pozo-Rosich P. OnabotulinumtoxinA: an effective tool in the therapeutic arsenal for chronic migraine with medication overuse. Front Neurol. 2018;9:808.","DOI":"10.3389\/fneur.2018.00808"},{"key":"452_CR42","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0333102414561873","volume":"35","author":"E Cernuda-Moroll\u00f3n","year":"2015","unstructured":"Cernuda-Moroll\u00f3n E, Ram\u00f3n C, Larrosa D, Alvarez R, Riesco N, Pascual J. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. 2015;35:864\u20138.","journal-title":"Cephalalgia"},{"key":"452_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1129-2377-16-S1-A89","volume":"16","author":"C Cesaretti","year":"2015","unstructured":"Cesaretti C, Molesti E, Lolli F, Amantini A, Lori S. O034. Type of pain and onabotulinumtoxin-A in chronic migraine: four years of follow-up. J Headache Pain. 2015;16:1\u20132.","journal-title":"J Headache Pain"},{"key":"452_CR44","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/head.13630","volume":"59","author":"J Ching","year":"2019","unstructured":"Ching J, Tinsley A, Rothrock J. Prognosis following discontinuation of onabotulinumA therapy in \u201csuper-responding\u201d chronic migraine patients. Headache. 2019;59:1279\u201385.","journal-title":"Headache"},{"key":"452_CR45","first-page":"S248","volume":"40","author":"I Corbelli","year":"2019","unstructured":"Corbelli I, Bernetti L, Verzina A, et\u00a0al. Sustained efficacy and safety of onabotulinumtoxin Type A in chronic migraine patients: a multicentric prospective real-life study. Neurol Sci. 2019;40:S248.","journal-title":"Neurol Sci"},{"key":"452_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000499764","volume":"81","author":"M de Tommaso","year":"2019","unstructured":"de Tommaso M, Brighina F, Delussi M. Effects of botulinum toxin A on allodynia in chronic migraine: an observational open-label two-year study. Eur Neurol. 2019;81:37\u201346.","journal-title":"Eur Neurol"},{"key":"452_CR47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ene.13523","volume":"25","author":"C Dom\u00ednguez","year":"2018","unstructured":"Dom\u00ednguez C, Pozo-Rosich P, Torres-Ferr\u00fas M, et\u00a0al. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol. 2018;25:411\u20136.","journal-title":"Eur J Neurol"},{"key":"452_CR48","unstructured":"Evangelista L, Guezoni S, Pellesi L, et\u00a0al. The profile of super-responders to onabotulinumtoxin A for chronic migraine: data from an observational study. J Headache Pain. 2017;18(Suppl 1):111. Abstract P137.."},{"key":"452_CR49","first-page":"242","volume":"39","author":"V Favoni","year":"2019","unstructured":"Favoni V, Calabro C, Asioli GM, et\u00a0al. Can onabotulinumtoxina be successfully stopped in chronic migraine responders? Cephalalgia. 2019;39:242.","journal-title":"Cephalalgia"},{"key":"452_CR50","first-page":"59","volume":"35","author":"R Forbes","year":"2015","unstructured":"Forbes R, Kinney M, Singhal M, Forbes DL, Sugrue J. Treating chronic migraine with botulinum toxin Type A (BTX-A)-do affective disorders influence 12 month outcome? Cephalalgia. 2015;35:59.","journal-title":"Cephalalgia"},{"key":"452_CR51","first-page":"20","volume":"36","author":"JB Gomez-Galvan","year":"2016","unstructured":"Gomez-Galvan JB. Differences in response to onabotulinumtoxin a treatment according to the headache days suffered per month. Cephalalgia. 2016;36:20\u20131.","journal-title":"Cephalalgia"},{"key":"452_CR52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/head.13693","volume":"60","author":"A Gonzalez-Martinez","year":"2020","unstructured":"Gonzalez-Martinez A, Rodriguez Vazquez E, de la Red Gallego H, et\u00a0al. Association between personality traits and onabotulinumtoxin A response in patients with chronic migraine. Headache. 2020;60:153\u201361.","journal-title":"Headache"},{"key":"452_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10072-015-2140-2","volume":"36","author":"L Grazzi","year":"2015","unstructured":"Grazzi L, Usai S. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. Neurol Sci. 2015;36:33\u20135.","journal-title":"Neurol Sci"},{"key":"452_CR54","first-page":"21","volume":"36","author":"L Grazzi","year":"2016","unstructured":"Grazzi L, D\u2019Amico D, Raggi A, Leonardi M, Andrasik F. Botulinum a toxin for treatment of chronic migraine with medication overuse. Cephalalgia. 2016;36:21\u20132.","journal-title":"Cephalalgia"},{"key":"452_CR55","first-page":"265","volume":"39","author":"B Jenkins","year":"2019","unstructured":"Jenkins B, Cheng S, Limberg N, Hutton E. Will refractory migraine patients in the real world respond to Erenumab? Cephalalgia. 2019;39:265\u20136.","journal-title":"Cephalalgia"},{"key":"452_CR56","first-page":"53","volume":"35","author":"SR Jimenez","year":"2015","unstructured":"Jimenez SR, Wilson MC. Safety and efficacy of botulinum toxin for chronic migraine in the elderly. Cephalalgia. 2015;35:53.","journal-title":"Cephalalgia"},{"key":"452_CR57","first-page":"333","volume":"37","author":"G Kennedy","year":"2017","unstructured":"Kennedy G, Nightingale H, Richardson S. Longer term outcomes for patients with chronic migraine treated with OnabotulinumtoxinA BOTOX and implications for a Headache Service: Real-life data for 120 patients treated at Sunderland Royal Hospital, UK. Cephalalgia. 2017;37:333.","journal-title":"Cephalalgia"},{"key":"452_CR58","first-page":"47","volume":"36","author":"G Lambru","year":"2016","unstructured":"Lambru G, Trimboli M, Andreou AP, Murphy M, Al-Kaisy A. Long-term experience of onabotulinumtoxina in a large series of chronic migraine patients. Cephalalgia. 2016;36:47.","journal-title":"Cephalalgia"},{"key":"452_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcma.2013.09.006","volume":"77","author":"K Lin","year":"2014","unstructured":"Lin K, Chen S, Fuh J, Wang Y, Wang S. Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study. J Chinese Med Assoc. 2014;77:10\u20135.","journal-title":"J Chinese Med Assoc"},{"key":"452_CR60","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/head.12657","volume":"55","author":"K Maasumi","year":"2015","unstructured":"Maasumi K, Thompson NR, Kriegler JS, Tepper SJ. Effect of onabotulinumtoxinA injection on depression in chronic migraine. Headache. 2015;55:1218\u201324.","journal-title":"Headache"},{"key":"452_CR61","first-page":"409","volume":"39","author":"S Naegel","year":"2019","unstructured":"Naegel S, Scheffler A, Wurthmann SF, Holle D. Erenumab for migraine treatment \u2013 first real world data from Germany. Cephalalgia. 2019;39:409.","journal-title":"Cephalalgia"},{"key":"452_CR62","unstructured":"Navarrete Perez JJ, Ruiz Pi\u00f1ero M, G\u00f3mez L\u00f3pez de San Rom\u00e1n C, et\u00a0al. Wearing-off effect of onabotulinumtoxina in chronic migraine: evaluation in a series of 117 patients. Eur J Neurol. 2017;24:547."},{"key":"452_CR63","doi-asserted-by":"crossref","unstructured":"Pedraza MI, de la Cruz C, Ruiz M, et\u00a0al. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. SpringerPlus. 2015;4:176.","DOI":"10.1186\/s40064-015-0957-z"},{"key":"452_CR64","first-page":"257","volume":"33","author":"AC Ramirez","year":"2013","unstructured":"Ramirez AC, Alvarez FI, Volcy M. Efficacy of botulinum toxin type a botoxA\u00ae for chronic migraine, results from a headache center in Medellin- Colombia. Cephalalgia. 2013;33:257.","journal-title":"Cephalalgia"},{"key":"452_CR65","doi-asserted-by":"crossref","unstructured":"Ranoux D, Martin\u00e9 G, Espagne-Dubreuilh G, Amilhaud-Bordier M, Caire F, Magy L. OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study. J Headache Pain. 2017;18:75.","DOI":"10.1186\/s10194-017-0781-7"},{"key":"452_CR66","first-page":"231","volume":"39","author":"L Robbins","year":"2019","unstructured":"Robbins L. CGRP antagonists for chronic migraine: early results. Cephalalgia. 2019;39:231.","journal-title":"Cephalalgia"},{"key":"452_CR67","first-page":"258","volume":"39","author":"J Robblee","year":"2019","unstructured":"Robblee J, Mendez N, Potter J, Slonaker J, Starling AJ. Post-market observational study of patient experience with erenumab. Cephalalgia. 2019;39:258\u20139.","journal-title":"Cephalalgia"},{"key":"452_CR68","doi-asserted-by":"crossref","unstructured":"Santoro A, Tanzi M, Miscio A, Copetti M, Leone M. P025. Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real life evaluation of 113 patients. J Headache Pain. 2015;16(Suppl 1):A182.","DOI":"10.1186\/1129-2377-16-S1-A182"},{"key":"452_CR69","doi-asserted-by":"crossref","unstructured":"Santoro A, Copetti M, Miscio AM, Leone MA, Fontana A. Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurol Sci. 2020;41(7):1809\u201320.","DOI":"10.1007\/s10072-020-04283-y"},{"key":"452_CR70","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.nrl.2016.09.004","volume":"33","author":"AC Sanz","year":"2018","unstructured":"Sanz AC, S\u00e1nchez-Mateos NM, Hern\u00e1ndez CS, et\u00a0al. Experience with botulinum toxin in chronic migraine. Neurologia. 2018;33:499\u2013504.","journal-title":"Neurologia"},{"key":"452_CR71","doi-asserted-by":"crossref","unstructured":"Sarchielli P, Romoli M, Corbelli I, et\u00a0al. Stopping onabotulinum treatment after the first two cycles might not be justified: results of a real-life monocentric prospective study in chronic migraine. Front Neurol. 2017;8:655.","DOI":"10.3389\/fneur.2017.00655"},{"key":"452_CR72","doi-asserted-by":"crossref","unstructured":"Stark C, Stark R, Limberg N, et\u00a0al. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. J Headache Pain. 2019;20(1):81.","DOI":"10.1186\/s10194-019-1030-z"},{"key":"452_CR73","unstructured":"Susie L, Maha A, Sarah M, Manjit M. Headache outcome measures in medically refractory chronic migraine patients treated with OnabotulinumtoxinA. J Headache Pain. 2018;19(Suppl 1):80. Abstract 025."},{"key":"452_CR74","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40267-018-0511-5","volume":"34","author":"F Velasco-Juanes","year":"2018","unstructured":"Velasco-Juanes F, G\u00f3mez-Esteban JC, Fern\u00e1ndez-Valle T, et\u00a0al. Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting. Drugs Ther Perspect. 2018;34:335\u201343.","journal-title":"Drugs Ther Perspect"},{"key":"452_CR75","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.13617","volume":"59","author":"F Vernieri","year":"2019","unstructured":"Vernieri F, Paolucci M, Altamura C, et\u00a0al. Onabotulinumtoxin-A in chronic migraine: should timing and definition of non-responder status be revised? Suggestions from a real-life Italian multicenter experience. Headache. 2019;59:1300\u20139.","journal-title":"Headache"},{"key":"452_CR76","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13760-018-0978-9","volume":"118","author":"P Yalinay Dikmen","year":"2018","unstructured":"Yalinay Dikmen P, Kosak S, Ilgaz Aydinlar E, Sagduyu Kocaman A. A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience. Acta Neurolog Belg. 2018;118:475\u201384.","journal-title":"Acta Neurolog Belg"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-022-00452-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-022-00452-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-022-00452-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T08:29:47Z","timestamp":1673944187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-022-00452-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1007\/s40122-022-00452-3","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}